Immunotherapy drug is well tolerated in lung cancer patients with limited physical function, study suggests
For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new ...
Nov 21, 2023
0
37